Literature DB >> 10560659

Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques.

S C Lee1, M L Zhao, A Hirano, D W Dickson.   

Abstract

Inducible nitric oxide synthase (iNOS) is involved in the generation of nitric oxide, a molecule with multiple biological activities. Although iNOS expression may be part of antimicrobial armamentarium, inappropriate expression of iNOS can potentially lead to damage to the host. In this report, we determined the expression of iNOS by immunocytochemistry in the hippocampus of the Alzheimer brains (AD) as well as in young and old normal brains. The results showed localization of iNOS immunoreactivity to Hirano bodies of the AD hippocampus. In addition, small granular iNOS immunoreactive profiles were detected associated with senile plaques and extracellular neurofibrillary tangles. In the hippocampus of control brains, morphologically similar profiles were immunoreactive for iNOS, but in far fewer numbers than in AD hippocampus. The results suggest that iNOS is expressed in a subset of pyramidal neurons in the AD hippocampus, and that iNOS may be involved in the pathogenesis of neuronal degeneration in AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10560659     DOI: 10.1097/00005072-199911000-00006

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  36 in total

1.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

Review 2.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

3.  Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

Authors:  Belén G Ramírez; Cristina Blázquez; Teresa Gómez del Pulgar; Manuel Guzmán; María L de Ceballos
Journal:  J Neurosci       Date:  2005-02-23       Impact factor: 6.167

Review 4.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

5.  Xanthoceraside attenuates amyloid β peptide₂₅₋₃₅-induced learning and memory impairments in mice.

Authors:  Ping Lu; Takayoshi Mamiya; Lingling Lu; Akihiro Mouri; Takashi Ikejima; Hyoung-Chum Kim; Li-Bo Zou; Toshitaka Nabeshima
Journal:  Psychopharmacology (Berl)       Date:  2011-07-07       Impact factor: 4.530

6.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 7.  Intrinsic regulation of brain inflammatory responses.

Authors:  Elena Galea; Michael T Heneka; Cinzia Dello Russo; Douglas L Feinstein
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

Review 8.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia.

Authors:  Erik Hjorth; Dan Frenkel; Howard Weiner; Marianne Schultzberg
Journal:  Int J Alzheimers Dis       Date:  2010-05-20

10.  The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.

Authors:  Abdur Rahman; Kaka Ting; Karen M Cullen; Nady Braidy; Bruce J Brew; Gilles J Guillemin
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.